Montrouge, France, March 24 (9:30 p.m. CET) 2023
Combined General Meeting of April 12, 2023
Methods of providing information and preparatory documents for the General Meeting
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – NASDAQ: DBVT), a French clinical-stage biopharmaceutical company, will hold its Combined General Meeting on Wednesday, April 12 at 10:00 a.m. (Paris time), at the Company’s headquarters, 177-181 Avenue Pierre Brossolette in Montrouge (92120).
The notice of meeting including the agenda, draft resolutions and terms of participation in the General Meeting was published in the BALO of March 8, 2023 (n° 2300429). The notice of meeting was published in the BALO on March 24, 2023 (n° 2300600) and in the Parisian Posters on March 24, 2023.
The information and preparatory documents for this Meeting are made available to the Company’s shareholders in accordance with the terms and within the time limits provided for by the applicable legal and regulatory provisions. The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the Company’s website (www.dbv-technologies.com).
Any shareholder wishing to receive these documents by post or electronically may request them up to the fifth day before the General Meeting, i.e. until Friday April 7, 2023 at midnight, Paris time, directly to the email address dedicated to the Company: [email protected] . For
bearer shareholders, this request must be accompanied by a certificate of registration in the securities accounts held by an intermediary mentioned in article L. 211-3 of the Monetary and Financial Code.
Broadcast of the General Assembly
On Wednesday April 12, 2023, from 10:00 a.m. (Paris time), the Shareholders’ Meeting will be broadcast live on the Company’s website www.dbv-technologies.com.
Shareholders will also be able to access the deferred retransmission of the Meeting on the Company’s website for two years following the holding of the General Meeting.
About DBV Technologies
DBV Technologies is developing Viaskin™, an experimental proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on Epicutaneous Immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company aims to safely transform the treatment of patients with food allergies. DBV Technologies’ food allergy programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies’ global headquarters are located in Montrouge, France, and its North American operations are based in Basking Ridge, NJ. The Company’s ordinary shares are traded on the B segment of Euronext Paris (symbol: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing half an ordinary share) are traded on the Nasdaq Global Select Market ( symbol: DBVT).
Forward-looking statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin™ Peanut as a treatment for children with peanut allergy and the potential benefits of EPIT™. These forward-looking statements and estimates do not constitute promises or guarantees and involve substantial risks and uncertainties and these may be affected by market conditions as well as other risks and uncertainties set forth in regulatory filings by DBV. Technologies with the Autorité des Marchés Financiers (“AMF”) as well as in documents and reports filed by DBV Technologies with the United States Securities and Exchange Commission (“SEC”), and in future filings and reports with the AMF and the SEC. Current and potential investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date of this document. Except as required by applicable law, DBV Technologies does not undertake to update or revise the information contained in this press release.
Investor contacts
Anne Pollack
DBV Technologies
+1 857-529-2363
Media contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
Attachment